Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled trial of clazakizumab in adults with end-stage kidney disease on dialysis
MOH_2024-09-24_013351Phase 3Recruiting
- Sponsor
- CSL Behring
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in end-stage kidney disease (ESKD) and cardiac morbidity comparing CSL300 with Placebo (2 arms). Primary endpoint: Composite cardiovascular outcome. Started Sep 2024; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
end-stage kidney disease (ESKD)cardiac morbidity
Beyond the preview
Go deeper on MOH_2024-09-24_013351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-24_013351.